Menopause Isn't One Thing. Neither Is Hormone Therapy.

Estrogen and progesterone receptors are found in nearly every organ: the brain, heart, bones, muscles, skin, gut, and bladder. So it makes sense that when these hormones shift, symptoms show up everywhere.

• Researchers have documented up to 72 menopause symptoms, with women experiencing about seven at a time.
• The most commonly reported symptoms involve the brain: brain fog, mood changes, irritability, anxiety, and disrupted sleep. Up to 80% of women report brain fog or mood changes during the transition.
• Symptoms last about 7.4 years on average, and roughly a third of women aged 65 to 79 still have hot flashes.

Many women don't know this. While most recognize hot flashes as menopause, fewer than half know that memory issues, anxiety, body aches, and urinary or vaginal symptoms can be part of it too.

The good news about brain fog: Studies show the cognitive dips of perimenopause are usually temporary and tend to stabilize afterward.

Because estrogen and progesterone receptors are found in nearly every organ, menopause is a whole-body transition. The Science review maps changes across nearly every system. Researchers note these effects occur independently of chronological age. Everyone's experience is different: which symptoms you have, when they start, how severe they are, and how long they last vary widely.

• Brain fog: trouble with memory, focus, and concentration
• Mood swings and irritability
• Anxiety and depression, especially in women with a prior history of depression

Brain-related symptoms are the most commonly reported symptoms of menopause.

• Insomnia
• Night sweats and hot flashes that fragment sleep
• Sleep-disordered breathing, including sleep apnea
• Restless legs

• Blood vessels become less elastic
• Blood pressure rises
• LDL cholesterol and triglycerides increase

• Slower metabolic rate
• A shift toward visceral (belly) fat
• Rising insulin resistance and metabolic syndrome risk

• An increase in low-grade, body-wide inflammation

• Loss of lean muscle mass
• Declining bone density, which raises osteoporosis and fracture risk
• Back and joint pain

• Vaginal dryness, itching, or burning
• Painful intercourse
• Urinary frequency, urgency, and leaking
• Recurrent urinary tract infections
• Gradual changes in kidney filtration

• Changes in gut microbial diversity
• Reflux, linked to weakening of the lower esophageal sphincter

• Thinner skin, hair, and nails
• Dry skin, eyes, and mouth

Symptoms last about 7.4 years on average, but many continue well into postmenopause. Roughly a third of women aged 65 to 79 still have hot flashes. Because these changes are real and lasting, menopause care shouldn't end when your periods do.

The review emphasizes that the features of your menopause carry important information:

• Timing: Earlier menopause, especially before 45, is linked to higher risk of heart disease, osteoporosis, and dementia.
• Type: Surgical menopause (removal of the ovaries) causes an abrupt hormone drop with its own health effects.
• Symptom burden: Women with more severe hot flashes are up to three times as likely to experience depressive symptoms, and they tend to develop diabetes earlier. Prolonged hot flashes are also linked to high blood pressure, insulin resistance, and unfavorable cholesterol.

The transition also brings a shift toward visceral (belly) fat, loss of muscle, and declining bone density. Together these raise inflammation and metabolic syndrome risk.

In other words, menopause isn't only something to get through. It's a window to identify risk early and act on it.

This is the review's most important message. There are more than 200 forms of menopause hormone therapy. They differ by type of estrogen, type of progestogen, dose, route (pill, patch, gel, or vaginal), timing, and whether they're taken cyclically or continuously. Each has its own balance of risks and benefits.

Much of the fear around hormone therapy traces back to the Women's Health Initiative (WHI) trial. It studied one specific regimen: oral conjugated equine estrogens plus a synthetic progestin called medroxyprogesterone acetate (MPA). Most participants were well past menopause. When that combination showed increased risks, the findings were applied to all hormone therapies. Prescriptions fell by more than 60%.

The review highlights several distinctions that matter:

• Route matters. Transdermal estradiol (patch or gel) bypasses the liver and carries a two- to four-fold lower blood clot risk than oral estrogen.
• The progestogen matters. MPA, the progestin used in WHI, is tied to most of that trial's poorer outcomes. Combinations using micronized progesterone have shown more favorable results for the brain.
• Timing matters. Starting hormone therapy closer to the menopause transition may lower cardiovascular risk, compared with starting many years later.
• Bone benefits are real. Systemic estrogen therapy reduces fractures by 20 to 40%.

In 2025, the U.S. FDA announced the removal of the boxed warning on hormone therapy. The International Menopause Society supported removing it for vaginal estrogen but not for systemic therapy, a reminder that the conversation is still evolving.

Hormone therapy also isn't the only option. Newer non-hormonal medications that target the brain's temperature-control pathway can reduce hot flashes for women who can't or prefer not to use hormones.

What hormone therapy is not: Trials have not shown it to be a treatment for cognitive decline. Its proven roles are relieving symptoms and protecting bone.

The authors argue that menopause care needs a precision medicine approach, much like modern breast cancer care. Your response to hormones may be shaped by:

• Your reproductive history. Women with severe PMS often have more intense perimenopause symptoms. Pregnancy complications such as preeclampsia are linked to more hot flashes and higher cardiovascular risk.
• Your hormone history. Past birth control and hormone use may influence how you respond to therapy later.
• Your genetics. Gene variants affecting how your body processes estrogen appear to influence symptom severity and treatment response.

They also challenge arbitrary time limits. Age alone shouldn't determine when someone stops hormone therapy, especially since many women over 65 still have symptoms. Stopping is also linked to faster bone loss.

At Arete Women's Integrative Medicine, menopause care is personal. I take the time to understand your symptoms, your reproductive and hormone history, and your metabolic, bone, and cardiovascular health. Then I build a plan around you, including hormone therapy when appropriate, non-hormonal options, and nutrition, strength, and sleep strategies.

I see patients in person at my office in Ridgway, Colorado, and via telehealth across the state.